CD‐sens and clinical changes during withdrawal of Xolair after 6 years of treatment

Background:  Many clinical trials with omalizumab, Xolair, have been reported but the treatment period has always been short, i.e.

Saved in:
Bibliographic Details
Published in:Allergy 2007-10, Vol.62 (10), p.1175-1181
Main Authors: Nopp, A., Johansson, S. G. O., Ankerst, J., Palmqvist, M., Öman, H.
Format: Article
Language:English
Subjects:
Adult
Aged
Allergens - immunology
Anti-Asthmatic Agents - administration & dosage
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Asthma - drug therapy
Asthma - immunology
Basophils - immunology
CD-sens
CD203c
CD63
Clinical Medicine
Dose-Response Relationship, Drug
Female
Flow Cytometry
Humans
immunoglobulin E
Immunoglobulin E - blood
Klinisk medicin
Longitudinal Studies
Lungmedicin och allergi
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Middle Aged
Omalizumab
Respiratory Medicine and Allergy
Rhinitis, Allergic, Seasonal - blood
Rhinitis, Allergic, Seasonal - drug therapy
Rhinitis, Allergic, Seasonal - immunology
Substance Withdrawal Syndrome - immunology
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:  Many clinical trials with omalizumab, Xolair, have been reported but the treatment period has always been short, i.e.
ISSN:0105-4538
1398-9995
1398-9995
0108-1675
DOI:10.1111/j.1398-9995.2007.01476.x